These methodological shortcomings reduce certainty regarding causality and preclude strong recommendations at this stage, especially for individuals at low cardiovascular risk
The ability of semaglutide to modulate or reverse multiple pathogenic pathways in complex disease may be one of its defining characteristics, concluded the authors.
For healthcare professionals, this approval provides a new treatment option to help us address cardiovascular residual risk that remains for patients on current standard of care. Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight, said John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research
It may also allow other serious arrhythmias to occur
Chicken breast delivers 31 grams of protein per 165 calories
Accessed online at Health benefits of glutathione
